Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)



Relypsa, Inc. (NASDAQ:RLYP) is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa Inc. (NASDAQ:RLYP) stock performance was 2.66% in last session and finished the day at $43.62. Traded volume was 126,739.00 shares in the last session and the average volume of the stock remained 113,686.00 shares. Relypsa Inc. (NASDAQ:RLYP) insider ownership is 0.30%.

On February 13, 2014, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and year ended December 31, 2013. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose 0.68% to $17.65 yesterday on volume of 1.24 million shares. The intra-day range of the stock was $16.79 – $18.13. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has a market capitalization of 587.46 million.

On March 11, 2014, OHR Pharmaceutical Inc. (NASDAQ:OHRP) agreed to amend the 291,671 outstanding Class J common stock purchase warrants (the “Class J Warrants”), to provide for cashless exercise. OHR Pharmaceutical Inc. (NASDAQ:OHRP)’s stock on March 14, 2014 reported a higher of 6.33% to the closing price of $19.65. Its fifty two weeks range is $4.11 – $19.99. The total market capitalization recorded 390.50 million. The overall volume in the last trading session was 330,145.00 shares. In its share capital, OHR Pharmaceutical Inc. (NASDAQ:OHRP) has 19.87 million outstanding shares.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. On Friday, shares of Xencor Inc. (NASDAQ:XNCR) advanced 1.61% to close the day at $13.90. Company return on investment (ROI) is 4.30% and its monthly performance is recorded as 52.08%. Xencor Inc. (NASDAQ:XNCR) quarterly revenue growth is 58.68%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone